The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease
We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)α, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797086856560508928 |
|---|---|
| author | Soedamah-Muthu, S Charlton-Menys, V Bao, W Schalkwijk, C Da Stehouwer, C Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Fuller, J Demicco, D Preston, G |
| author_facet | Soedamah-Muthu, S Charlton-Menys, V Bao, W Schalkwijk, C Da Stehouwer, C Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Fuller, J Demicco, D Preston, G |
| author_sort | Soedamah-Muthu, S |
| collection | OXFORD |
| description | We examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)α, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFα, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFα 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFα, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011. |
| first_indexed | 2024-03-07T02:27:55Z |
| format | Journal article |
| id | oxford-uuid:a641d9b4-b933-48c2-8857-4f2aa37b041b |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T02:27:55Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:a641d9b4-b933-48c2-8857-4f2aa37b041b2022-03-27T02:45:56ZThe effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart diseaseJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:a641d9b4-b933-48c2-8857-4f2aa37b041bEnglishSymplectic Elements at Oxford2011Soedamah-Muthu, SCharlton-Menys, VBao, WSchalkwijk, CDa Stehouwer, CColhoun, HBetteridge, DDurrington, PHitman, GNeil, HLivingstone, SFuller, JDemicco, DPreston, GWe examined the effect of atorvastatin (and placebo) on tumour necrosis factor (TNF)α, soluble vascular cell adhesion molecule-1 (sVCAM-1) and soluble intercellular cell adhesion molecule-1 (sICAM-1) in patients with type 2 diabetes without prior cardiovascular disease (CVD) and investigated whether adhesion molecules were associated with incident CVD. Baseline and follow-up concentrations of TNFα, sVCAM-1 and sICAM-1 were measured in patients from the Collaborative AtoRvastatin Diabetes Study (CARDS). Patients had a mean age of 61 years (standard deviation = 8) and 70% were men. TNFα 2.20 pg/mL (1.82-2.86), sVCAM-1 865 ng/mL (729-1059) and sICAM-1 619 ng/mL (533-753) concentrations (median, interquartile range 25, 75%) were similar at baseline in atorvastatin (given values) and placebo groups and not significantly different at 2 years. The multivariable hazard ratios for the associations between sVCAM-1 and sICAM-1 (doubling the concentration) and CVD were, 0.82 (95% confidence interval (CI) 0.66-1.0) and 0.59 (95% CI 0.50-0.71), respectively. In conclusion atorvastatin had no significant effect on TNFα, sVCAM-1 or sICAM-1 levels in type 2 diabetic patients without a prior history of CVD compared with placebo. In addition, both sVCAM-1 and sICAM-1 concentrations were associated with a decreased risk of CVD. © SAGE Publications 2011. |
| spellingShingle | Soedamah-Muthu, S Charlton-Menys, V Bao, W Schalkwijk, C Da Stehouwer, C Colhoun, H Betteridge, D Durrington, P Hitman, G Neil, H Livingstone, S Fuller, J Demicco, D Preston, G The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title | The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title_full | The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title_fullStr | The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title_full_unstemmed | The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title_short | The effect of atorvastatin therapy on tumour necrosis factor-α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| title_sort | effect of atorvastatin therapy on tumour necrosis factor α and vascular adhesion molecules in patients with type 2 diabetes mellitus with no prior history of coronary heart disease |
| work_keys_str_mv | AT soedamahmuthus theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT charltonmenysv theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT baow theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT schalkwijkc theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT dastehouwerc theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT colhounh theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT betteridged theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT durringtonp theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT hitmang theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT neilh theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT livingstones theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT fullerj theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT demiccod theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT prestong theeffectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT soedamahmuthus effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT charltonmenysv effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT baow effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT schalkwijkc effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT dastehouwerc effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT colhounh effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT betteridged effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT durringtonp effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT hitmang effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT neilh effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT livingstones effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT fullerj effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT demiccod effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease AT prestong effectofatorvastatintherapyontumournecrosisfactoraandvascularadhesionmoleculesinpatientswithtype2diabetesmellituswithnopriorhistoryofcoronaryheartdisease |